Induced high expression of PD‐L1 nb in ESCs and tumors enhanced safety and efficiency while limiting secretion, thereby improving the tumor microenvironment and the effectiveness of the tumor vaccine compared to treatments with anti‐PD‐1 antibodies. This evidence concerns the gene CD274 and neoplasm.